Outracing 2 giant rivals, J&J touts promising PhIII Invokana data as a game-changer for kidney disease risks

In a race to expand market share against two top rivals in the diabetes field, J&J just scored one in the win column. And they’ll play it for all it’s worth in an attempt to revive flagging sales.